Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $11

Benzinga · 3d ago
Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.